Downregulation of GLIPR1 and gene knockdown experiments in various leukemia cell lines treated with the small drug SB225002 (N-(2-hydroxy-4-nitrophenyl)-N’-(2-bromophenyl)urea) resulted in elevated production of ROS, a decrease in cell proliferation linked to an increased level of apoptosis due to GLIPR1 silencing, and amplified drug resistance[138]. This evidence concerns the gene GLIPR1 and leukemia.